Tuesday - April 28, 2026
GSK's Investigational Liver Therapy, Efimosfermin, Receives US FDA Breakthrough Therapy and EMA Priority Medicines Designations for MASH
April 28, 2026
LONDON, England, April 28 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 27, 2026:

* * *

GSK's investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH

* Phase II data show once-monthly efimosfermin improved liver fibrosis (scarring), a key driver of disease progression in metabolic dysfunction-associated steatoh . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products